rs1802059 — MTRR

MTRR c.1911G>A — A Synonymous Variant With a Heart Risk Signal

The MTRR gene (methionine synthase reductase) encodes the enzyme responsible for keeping methionine synthase (MTR) operational. MTR converts homocysteine to methionine using methylcobalamin ¹¹ The methyl-carrying, active form of vitamin B12 (active B12) as a cofactor, but during each catalytic cycle B12 becomes oxidized and inactive. MTRR reactivates it, sustaining the methylation cycle that underpins DNA synthesis, neurotransmitter regulation, and epigenetic gene control. Disruptions to MTRR function allow homocysteine to accumulate and SAM (the universal methyl donor) to fall — outcomes with consequences in developing embryos that are especially dependent on tight methylation control.

rs1802059 (c.1911G>A) is a synonymous change that does not alter the amino acid at position 637 (p.Ala637=), so it is classified as benign by ClinVar for hereditary B12 deficiency. Yet two independent Han Chinese case-control studies have found the A allele associated with substantially elevated congenital heart disease (CHD) risk in offspring — the homozygous AA genotype carrying a five- to nearly four-fold increased odds in one study and the maternal carrier analysis respectively. This is a classic example of a synonymous variant that may influence splicing efficiency, mRNA stability, or co-translational folding without producing a detectable amino acid change, but whose downstream effect on MTRR activity matters most during embryonic cardiac development.

The Mechanism

Synonymous variants in coding regions are not functionally silent. They can alter exonic splicing enhancer or silencer sequences, change local mRNA secondary structure, or shift the codon usage to a rarer tRNA that slows translation elongation at critical co-translational folding points. For rs1802059 specifically, no biochemical or cell-line functional study has yet isolated the mechanism — but the epidemiological signal is consistent across two independent Han Chinese cohorts and biologically coherent: reduced MTRR activity impairs B12-dependent homocysteine remethylation, and the embryonic heart is among the most epigenetically sensitive tissues during organogenesis. The CHD associations parallel those seen for other functional MTRR variants (rs10380 His595Tyr, OR 2.27; rs1532268, aOR 3.18), suggesting the gene as a whole is a meaningful node in cardiac developmental risk.

The Evidence

The primary evidence comes from two complementary hospital-based case-control studies in Han Chinese populations. Wei et al. 2023²² Wei et al. 2023
Wei J et al. Maternal MTRR gene polymorphisms and CHD risk. J Matern Fetal Neonatal Med, 2023 studied 740 mothers of CHD-affected children versus 683 healthy controls and found that the maternal G/A genotype carried aOR 1.41 and A/A genotype aOR 3.95 for offspring CHD. Seven MTRR haplotypes — combinations including rs1802059 — showed statistically significant associations with CHD occurrence. Li et al. 2024³³ Li et al. 2024
Li L et al. Maternal folic acid supplementation and offspring MTRR polymorphism and CHD. J Health Popul Nutr, 2024 analyzed 595 CHD-affected children and 605 healthy child controls, finding that the offspring AA genotype carried OR 5.13 (95% CI 2.15–12.23) and GA OR 1.81 (95% CI 1.35–2.43) compared to GG. Crucially, the interaction term between maternal folic acid supplementation and rs1802059 variant status was significant at OR 0.38 (95% CI 0.15–0.94) — meaning that among offspring carrying the A allele, maternal folic acid supplementation substantially reduced CHD risk.

The evidence level is emerging: both studies are case-control designs in a single ethnic group, functional mechanism has not been biochemically confirmed, and replication in non-Han populations has not been reported. The effect sizes are nonetheless striking and the folic acid interaction is highly clinically relevant.

Practical Implications

The strong interaction between maternal folic acid supplementation and the rs1802059 risk genotype is the most actionable finding. This variant is in MTRR — the B12 recycling enzyme. The standard methylation cycle intervention toolkit applies: methylfolate (bypassing any MTHFR conversion bottleneck), active B12 forms (methylcobalamin or hydroxocobalamin to reduce dependence on MTRR recycling), and homocysteine monitoring as a functional readout. Periconceptional supplementation is the highest-priority action for individuals planning pregnancy. Outside of pregnancy, maintaining adequate one-carbon cycle cofactors reduces the downstream consequences of any impaired MTRR recycling capacity.

Interactions

rs1802059 sits within MTRR alongside three other functionally characterized variants: rs1801394 (A66G, p.Ile22Met — reduces enzyme efficiency), rs10380 (His595Tyr — impairs B12 reactivation chemistry), and rs162049 (intronic — reduces MTRR protein expression). Carrying multiple MTRR risk alleles compounds the reduction in B12 recycling capacity. The most clinically relevant interaction is with MTHFR C677T (rs1801133): impaired methylfolate supply combined with impaired B12 recycling creates dual pressure on the homocysteine remethylation pathway that neither variant alone produces.